Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Specimen Handling 200Magnetic Resonance Spectroscopy 151Biopsy 113Nivolumab 40Immunoglobulin G 40Disulfides 40Cisplatin 38Cyclophosphamide 37Platinum 36Paclitaxel 361,2-diaminocyclohexaneplatinum II citrate 36Carboplatin 35Taxes 34Radiation 34X-Rays 29Radiotherapy 28pembrolizumab 27Doxorubicin 25Bevacizumab 24olaparib 22atezolizumab 22Gemcitabine 22Vincristine 19Prednisone 19fludarabine 18Ipilimumab 18CTLA-4 Antigen 18venetoclax 17durvalumab 17Phantoms, Imaging 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × TAK-243 × 30 days × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡